TriangleNivolumab or Pembrolizumab… (NCT04114136)
Nivolumab or Pembrolizumab (dependent upon approved indication) trial for Melanoma (NCT04114136). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with specified advanced cancers where pembrolizumab or nivolumab alone is standard care. Prior PD1 or PD-L1 immunotherapy excludes participation. An accessible tumor is required.
The idea: random assignment adds metformin, rosiglitazone, or neither to checkpoint immunotherapy. Researchers test whether these metabolic drugs reduce tumor oxygen consumption and improve immune-cell function. Biopsies occur before treatment and around five weeks later. Treatment can continue for two years; scans measure response.
This phase 2 study plans 72 patients. Dan Zandberg leads at UPMC Hillman, Pittsburgh, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.